Stay updated with breaking news from Thomas Gad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now directly owns 197,681 […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares of the […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 7,351 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now owns 232,681 shares in the company, valued at […]
Wedbush reiterated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research report released on Monday morning, RTT News reports. They currently have a $18.00 price objective on the stock, up from their prior price objective of $12.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.19) […]
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) were up 2.8% on Tuesday . The company traded as high as $12.50 and last traded at $12.45. Approximately 32,320 shares changed hands during trading, a decline of 92% from the average daily volume of 411,775 shares. The stock had previously closed at $12.11. Analysts […]